Skip to main content
Tuesday, November 17, 2026Nov 17

Promising new gene therapies for sickle cell are out of reach in countries where they’re needed most

Gautam Dongre, of the National Alliance of Sickle Cell Organizations, sits for a portrait with his daughter, Sumedha, 13, at their residence in Nagpur, India, Wednesday, Dec. 6, 2023. Dongre recalls how his newborn son, Girish, cried constantly from stomach and leg pain. Doctors couldn’t figure out what was wrong and didn’t diagnose him with sickle cell for 2 1/2 years. When Sumedha was born, he and his wife had her tested immediately and learned she had the disease too. (AP Photo/Ajit Solanki)
Gautam Dongre, of the National Alliance of Sickle Cell Organizations, sits for a portrait with his daughter, Sumedha, 13, at their residence in Nagpur, India, Wednesday, Dec. 6, 2023. Dongre recalls how his newborn son, Girish, cried constantly from stomach and leg pain. Doctors couldn’t figure out what was wrong and didn’t diagnose him with sickle cell for 2 1/2 years. When Sumedha was born, he and his wife had her tested immediately and learned she had the disease too. (AP Photo/Ajit Solanki)


Gautam Dongre’s two children in India and Pascazia Mazeze’s son in Tanzania live with an inherited blood disorder that turns blood cells into instruments of pain.

New gene therapies promise a cure for sickle cell disease, and Dongre says he’s “praying the treatment should come to us.”

But experts say the one-time treatment is out of reach in India and Africa — places where the disease is most common. Vast inequities cut much of the world off from gene therapy in general.

While access to all sorts of medicine is limited in developing countries, the problem is especially acute with these therapies, some of the most expensive treatments in the world.